Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer.

MLA

Ducoulombier, Simon, et al. “Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer.” Anticancer Research, vol. 37, no. 12, Dec. 2017, pp. 6879–86. EBSCOhost, https://doi.org/10.21873/anticanres.12150.

APA

Ducoulombier, S., Golfier, F., Colomban, O., Benayoun, D., Bolze, P.-A., Tod, M., & You, B. (2017). Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer. Anticancer Research, 37(12), 6879–6886. https://doi.org/10.21873/anticanres.12150

Chicago

Ducoulombier, Simon, François Golfier, Olivier Colomban, David Benayoun, Pierre-Adrien Bolze, Michel Tod, and Benoit You. 2017. “Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer.” Anticancer Research 37 (12): 6879–86. doi:10.21873/anticanres.12150.